| |  Online-Ressource |
|---|
| Verfasst von: | Ohlmann, Carsten-Henning [VerfasserIn]  |
|---|
| | Merseburger, Axel S. [VerfasserIn] |
|---|
| | Suttmann, Henrik [VerfasserIn] |
|---|
| | Schilling, David Alexander [VerfasserIn] |
|---|
| | Trojan, Lutz [VerfasserIn] |
|---|
| | Kempkensteffen, Carsten [VerfasserIn] |
|---|
| | Corvin, Stefan [VerfasserIn] |
|---|
| | Mathers, Michael J. [VerfasserIn] |
|---|
| | Bastian, Patrick J. [VerfasserIn] |
|---|
| Titel: | Novel options for the treatment of castration-resistant prostate cancer |
|---|
| Verf.angabe: | Carsten-H. Ohlmann, Axel S. Merseburger, Henrik Suttmann, David Schilling, Lutz Trojan, Carsten Kempkensteffen, Stefan Corvin, Michael J. Mathers, Patrick J. Bastian |
|---|
| Jahr: | 2012 |
|---|
| Umfang: | 9 S. |
|---|
| Fussnoten: | Published online: 20 November 2011 ; Gesehen am 26.06.2018 |
|---|
| Titel Quelle: | Enthalten in: World journal of urology |
|---|
| Ort Quelle: | Berlin : Springer, 1983 |
|---|
| Jahr Quelle: | 2012 |
|---|
| Band/Heft Quelle: | 30(2012), 4, Seite 495-503 |
|---|
| ISSN Quelle: | 1433-8726 |
|---|
| Abstract: | Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials. |
|---|
| DOI: | doi:10.1007/s00345-011-0796-7 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: http://dx.doi.org/10.1007/s00345-011-0796-7 |
|---|
| | Volltext: https://link.springer.com/article/10.1007/s00345-011-0796-7 |
|---|
| | DOI: https://doi.org/10.1007/s00345-011-0796-7 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1576851176 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Novel options for the treatment of castration-resistant prostate cancer / Ohlmann, Carsten-Henning [VerfasserIn]; 2012 (Online-Ressource)
